C4 Therapeutics (CCCC) Q2 2026 earnings — TrendMatrix coverage
IN LINEEPS — vs -$0.23 estVerdict Hold → Sell
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Event detail · Q2 2026
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.23
- Surprise
- —
- Score at report (before → after)
- 4.3 → 4.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Report record · Q2 2026
How the report landed
TrendMatrix's engine moved from Hold (4.3/10) to Sell at 4.2/10 after the report.
Around the report
Coverage in the report window
- C4 Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate, Sales $6.641M Beat $4.000M Estimate — benzinga, 2026-08-11